Cleveland Clinic Foundation Cleveland Clinic (19)

Cleveland, Ohio 44195

0 studies enrolling now · 4 studies all time

What they study most

PI3K Pathway Activated Tumors, PTCH1 or SMO Activated Solid and Hematologic Tumors, Solid Tumor and Hematologic Malignancies, Tumor Pathway Activations Inhibited by Dovitinib

Studies at this site

• MEK162 for Patients With RAS/RAF/MEK Activated Tumors — Completed
• BKM120 for Patients With PI3K-activated Tumors — Completed
• Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib — Completed
• LDE225 for Patients With PTCH1 or SMO Mutated Tumors — Stopped early